Background: Atypical antipsychotic use among children and adolescents is a cause for concern secondary to metabolic adverse effects. There have been reports of weight gain, metabolic syndrome, dyslipidemia, glucose abnormalities, and decreased insulin sensitivity in children aged 4 to 19 years using atypical antipsychotics. Objective: To determine the prevalence of antidiabetic and antilipidemic medication use among children and adolescents receiving atypical antipsychotics and to evaluate whether the odds of receiving antidiabetic and antilipidemic medication differs among atypical antipsychotic agents. Methods: This retrospective cross-sectional study included Virginia Medicaid beneficiaries (2-17 years) continuously enrolled from August 1, 2010, to July 31, 2011. The participants were categorized into atypical antipsychotic exposed and unexposed. The prevalence of antidiabetic and antilipidemic medication use within the groups was computed. Logistic regression was used to calculate the odds of receiving antidiabetic or antilipidemic medication after controlling for age, sex, and race. Results: A total of 299593 and 4922 beneficiaries were identified in unexposed and exposed groups, respectively. The prevalence of antidiabetic medication use was 0.32% in the unexposed and 1.40% in the exposed group (P < 0.0001). Prevalence of antilipidemic medication use was 0.09% in the unexposed and 0.35% in the exposed group (P < 0.0001). Risperidone and quetiapine users had lower odds than olanzapine users of receiving antidiabetic medication. No differences between the odds of receiving antilipidemic medication among the different antipsychotics (P = 0.1653) were observed. Conclusions: Prevalence of antidiabetic and antilipidemic medication use was significantly higher among children and adolescent atypical antipsychotic users in a Virginia Medicaid population.
Introduction
One in 5 children, 13 to 18 years of age, have a serious mental disorder, 1 whereas 1 in 10 children suffer from behavioral and mood disorders. 1, 2 Based on data from the Medical Expenditure Panel Survey, the percentage of youths who received any mental health service increased from 9.2% between 1996 and 1998 to 13.3% between 2010 and 2012. 3 Antipsychotics have become the mainstay of treatment for a number of disorders (eg, schizophrenia, bipolar disorder, depression, disruptive behavior disorders). 4 Visits resulting in a prescription for an antipsychotic medication per 100 persons increased from 0.24 in children and 0.78 in adolescents (1993-1998) to 1.83 in children and 3.76 in adolescents (2005) (2006) (2007) (2008) (2009) ). Disruptive behavior disorders were the most common mental health diagnoses for these visits among children (63%) and adolescents (33.7%) between 2005 and 2009. 4 Use of atypical antipsychotics, also known as secondgeneration antipsychotics, has increased because of the propensity to cause less adverse extrapyramidal symptoms compared with typical antipsychotics 5 and because of effectiveness in adults [6] [7] [8] [9] [10] [11] and children. 5 Of the total number of antipsychotics used in a pediatric population, 92% were atypical antipsychotics in 2002 4 and 96.7% in 2010. 12 As of 2015, the Food and Drug Administration (FDA) approved numerous atypical antipsychotics for pediatric use. Aripiprazole, olanzapine, quetiapine, and risperidone have been approved to treat pediatric bipolar mania and schizophrenia. [13] [14] [15] [16] Aripiprazole and risperidone have an indication for irritability associated with autism. 13, 16 Asenapine was approved for pediatric 1 Virginia Commonwealth University, VA, USA bipolar disorder 17 and paliperidone for schizophrenia in adolescents. 18 There has been increased concern about the metabolic adverse effects of atypical antipsychotics. Correll et al. 19 reported that atypical antipsychotics were associated with weight gain, obesity, metabolic syndrome, dyslipidemia, glucose abnormalities, and decreased insulin sensitivity from baseline to 12 weeks after initiation of atypical antipsychotics in children 4 to 19 years old. Total cholesterol levels increased by 15.58 mg/dL (95% CI = 6.88-24.28) in olanzapine users and 9.05 mg/dL (95% CI = 0.41-17.69) in quetiapine users. Triglyceride levels increased by 37 mg/dL (P = 0.01) in quetiapine users and 10 mg/dL (P = 0.04) in risperidone users. 19 Similarly, a study of 66 children showed significant increases in total cholesterol levels among olanzapine (P = 0.047) and quetiapine (P = 0.016) users. 20 Atypical antipsychotics have the tendency to cause rapid weight gain and increase in body mass index (BMI >95th percentile), leading to medical complications (eg, obesity [>7% increase in weight], hyperglycemia, dyslipidemia, and metabolic syndrome). 19 This is troubling because an increase in weight during childhood is a determinant of cardiovascular risk. 21 Childhood BMI and weight were significantly correlated with increase in weight, BMI, systolic blood pressure, insulin, and lipid levels during adulthood. 21 Childhood obesity is a predictor of adulthood obesity and diabetes 22 and is a risk factor for the development of type 2 diabetes mellitus and hyperlipidemia during childhood. 23 To the best of our knowledge, the prevalence of both antidiabetic and antilipidemic medication use among children and adolescents using atypical antipsychotics has not been characterized. The main objectives of this study were to determine the prevalence of antidiabetic and antilipidemic medication use among children and adolescents receiving atypical antipsychotics and to evaluate whether prevalence differs among atypical antipsychotics.
Methods

Study Design and Data Source
This retrospective cross-sectional study used Virginia Medicaid pharmacy claims obtained from the Department of Medical Assistance Services. All patient identifiers were removed to protect patient confidentiality. Participants were assigned unique identifiers to link them across files. The study was approved by the Virginia Commonwealth University Institutional Review Board, Office of Research Subjects Protection.
Study Population
Beneficiaries 2 to 17 years of age were included if they were continuously enrolled in the Medicaid system (fee-for-service and managed care) from August 1, 2010, to July 31, 2011. Participants were excluded if they had juvenile diabetes (ICD-9-CM code: 250.x1 or 250.x3). Those with paid pharmacy claims for typical antipsychotics (ie, haloperidol, thiothixene, chlorpromazine, fluphenazine, and perphenazine) were excluded because these agents are not associated with metabolic disturbances. Participants with 2 or more paid claims (30±5 days apart) for a single atypical antipsychotic were included in the antipsychotic-exposed group. Both new and previous users of atypical antipsychotics during the study period were included. Because one of the study objectives was to examine the odds of concomitant use of a specific atypical antipsychotic agent and antidiabetic and/or antilipidemic medication, those who used multiple atypical antipsychotics were excluded to ensure that participants were exposed only to a single atypical antipsychotic during the study period. Those with claims for newer antipsychotic agents (ie, lurasidone, paliperidone, iloperidone, asenapine) were not included in the study because these medications were not approved until shortly before the start of the study period.
Two groups were constructed for the study. The exposed group included all those who had 2 or more paid pharmacy claims for a single atypical antipsychotic. Participants without claims for antipsychotics comprised the unexposed group. Variables on the data set included unique patient identifier, drug name and strength, age, sex, and race. Each drug was identified using the Generic Code Number (GCN, First DataBank) that groups drugs with the same ingredients, strengths, dosage forms, and routes of administration.
Participants using antidiabetic or antilipidemic medications were identified using claims data. Antidiabetic agents included insulin, glimepiride, glyburide, glipizide, metformin, glipizide/metformin, glyburide/metformin, pioglitazone, pioglitazone/metformin, rosiglitazone, sitagliptin, acarbose, exenatide, and liraglutide. Antilipidemic agents included atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, cholestyramine, colestipol, niacin, ezetimibe, fenofibrate, and gemfibrozil. Participants included both new and existing users of antidiabetic and antilipidemic medications during the study period.
Those in the exposed group were further classified into 5 subgroups based on the atypical antipsychotic agent received. The subgroups were aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone users. Because olanzapine had the highest propensity to cause weight gain, dyslipidemia, and glucose imbalance, it was chosen as the reference group. 19, 20, 24 
Statistical Analyses
Descriptive statistics were used to summarize demographic variables. Categorical data were described using percentage and counts. Normal continuous data were described using means and standard deviations. χ 2 tests were performed to test for demographic differences between the exposed and unexposed groups. Fisher's exact test was used when the expected cell size was less than 5. The prevalence of antidiabetic and antilipidemic drug use between unexposed and exposed groups was compared using χ 2 tests. Logistic regression analyses, adjusted for age, sex, and race, were used to describe the relationship between exposure to atypical antipsychotics and antidiabetic and antilipidemic medication. Unadjusted and adjusted odds ratios (ORs) and 95% CIs were reported. All tests were performed at a significance level of 0.05 using SAS statistical software V9.3 (SAS Institute Inc, Cary, NC).
Results
The unexposed group contained pharmacy claims data on 355298 unique participants. After including only continuously enrolled participants, a total of 299593 unique individuals were included in the unexposed group. The exposed group contained claims data on 13756 unique participants. Based on the inclusion/exclusion criteria, the final sample included 4922 individuals ( Figure 1 ).
Baseline demographics of the exposed and unexposed groups are reported in Table 1 . The typical participant exposed to atypical antipsychotics was a Caucasian male patient, 12 to 17 years old, whereas a typical unexposed participant was a Caucasian or African American male, or female patient, 5 to 11 years of age. The unexposed group (mean = 8.23 years) was significantly younger than the exposed group (mean = 11.77 years). In the exposed group, most of the participants had claims for risperidone (48.76%), whereas the fewest had claims for olanzapine (2.58%). The mean (range) daily dose for oral solid forms was 10 mg (1-75 mg) for aripiprazole, 10 mg (1.25-30 mg) for olanzapine, 168 mg (12.5-1200 mg) for quetiapine, 1.3 mg (0.1-4 mg) for risperidone, and 70 mg (13-320 mg) for ziprasidone.
Prevalence of Antidiabetic Medication Use
During the study period, 957 of 299593 (0.32%) participants in the unexposed group and 69 of 4922 (1.4%) participants in the exposed group had paid claims for at least 1 antidiabetic medication (χ 2 = 168.96; df = 1; P < 0.0001). Caucasian male exposed to atypical antipsychotics were significantly more likely to have claims for antidiabetic agents ( Table 2 ). The most commonly used antidiabetic medications were metformin (96%), insulin (6%), and glipizide (3%). The unadjusted logistic regression analysis indicated that the odds of having a claim for antidiabetic medication for children and adolescents exposed to an atypical antipsychotic agent were 4.44 (95% CI = 3.47-5.68) times higher than in those not exposed (Table 3 ). After controlling for age, sex, and race, the odds were 2.76 (95% CI = 2.15-3.55; P < 0.0001).
The highest prevalence of concomitant antidiabetic medication use ( Table 4 ) was among ziprasidone users (8.23%) and the lowest was among risperidone users (0.46%). Among olanzapine users, hypothesized to have the highest prevalence of concomitant antidiabetic medication use, only 3.15% had claims for antidiabetic agents. The unadjusted regression model showed that the receipt of an antidiabetic medication was significantly associated with the individual atypical antipsychotic agent (χ 2 = 53.57; df = 4; P < 0.0001). The adjusted model indicated that risperidone and quetiapine users had significantly lower odds than olanzapine users to receive antidiabetic medication ( Table 5 ).
Prevalence of Antilipidemic Medication Use
During the year, 261 of the 299 593 (0.09%) participants in the unexposed group and 17 of the 4922 (0.35%) participants in the exposed group had paid claims for an antilipidemic medication (χ 2 = 35.41; df = 1; P < 0.0001). Demographics of participants on antilipidemic medication use are presented in Table 2 . Caucasian male patients in the exposed group were significantly more likely to have claims for antilipidemic medications. The most commonly prescribed antilipidemic medications were statins (65%), niacin (18%), and bile acid sequestrants (12%). The unadjusted logistic regression analysis indicated that the odds of having a claim for an antilipidemic medication for children exposed to an atypical antipsychotic medication were 3.97 (95% CI = 2.43-6.50) times higher than in those not exposed (Table 3 ). After controlling for age, sex, and race, the odds were 2.21 (95% CI = 1.34-3.64; P = 0.0018). The prevalence of antilipidemic medication use was highest among ziprasidone users (1.27%) and lowest among risperidone users (0.21%; Table 4 ). The adjusted logistic regression analysis showed that none of the agents was significantly different from olanzapine for antilipidemic medication use (χ 2 = 6.49; df = 4; P = 0.1653). 
Discussion
The study results show that the prevalence of antidiabetic and antilipidemic medication use was significantly higher among children and adolescents with claims for atypical antipsychotics compared with those without antipsychotic claims. Adjusted regression models showed that the odds of receiving antidiabetic and antilipidemic medications among atypical antipsychotic users were more than twice that for nonusers. Age, sex, and race were found to be significant predictors of receipt of antidiabetic and antilipidemic medications among atypical antipsychotic users. After controlling for these factors, the odds of use of antidiabetic medications were significantly higher among the exposed (OR = 2.76; 95% CI = 2.15-3.55). These results support the findings of Andrade et al 25 that the incidence of diabetes was more than 4 times higher among children and adolescents using atypical antipsychotics compared with those who were not. Our study results also indicate that the risk of receiving antidiabetic medication was significantly higher among Caucasian female patients exposed to atypical antipsychotics and increased with age. Because this study only focused on a Medicaid population, future research will be needed to validate the results of this study to a larger population.
The current literature presents varying results in terms of the propensity of each atypical antipsychotic to induce metabolic changes and glucose imbalance in children and adolescents. One study reported no major differences among olanzapine, risperidone, and quetiapine in inducing insulin resistance, 26 whereas other studies report that olanzapine 19, 24 and quetiapine 19 had higher propensities to be associated with increased glucose levels. Risperidone has also been reported to be associated with glucose imbalance. 27 Because the majority of studies were short term and the longer studies had very limited sample sizes, no conclusions were drawn in a meta-analysis of metabolic and endocrine effects of atypical antipsychotics conducted by Hert et al. 28 Our study found that risperidone and quetiapine users had the lowest likelihood of having concomitant antidiabetic medication claims, whereas exposure to ziprasidone was associated with the highest likelihood. Even though the study results are consistent with what was reported by Rubin et al, 29 we acknowledge that these results could be a reflection of the methodological limitations of observational studies. It is possible that clinicians considered patient-specific factors (eg, weight, lipid panel) and patient's current health status when selecting a particular antipsychotic agent. Therefore, patients with preexisting metabolic conditions or those who experienced antipsychotic-induced metabolic abnormalities could have been initiated on, or switched to, newer agents like ziprasidone. Because of the retrospective cross-sectional nature of this study, we could not determine if other atypical antipsychotics were prescribed before the study period. Thus, the findings related to individual antipsychotic agents may be reflective of practice patterns rather than real differences among the agent studied. This highlights the need for more long-term prospective trials.
Caucasian male patients, 12 to 17 years of age, exposed to atypical antipsychotics seemed to be at the highest risk of receiving antilipidemic medications. Even though the absolute prevalence (0.35%) of concomitant antipsychotic and antilipidemic claims was low, we can assume that most of it reflects the more severe form of hyperlipidemia requiring pharmacological treatment. According to the National Cholesterol Education Program (NCEP) guidelines, pharmacotherapy is reserved for children older than 10 years, with low-density lipoprotein levels exceeding 190 mg/dL. 30 Clinically, these numbers are probably extreme representations of hyperlipidemia, a known health risk factor. Even after controlling for observed differences between the groups, we found that the odds of concomitant antilipidemic medication use were significantly higher among patients exposed to an atypical antipsychotic. Even though studies have reported that olanzapine was associated with the highest change in lipid levels among children and adolescents, 19, 20 we failed to find any significant association between receipt of antilipidemic medication and specific antipsychotic agent. One possible reason could have been lack of power because of insufficient sample size within the subgroups. This issue could be addressed by future studies. An interesting pattern to note is the atypical antipsychotic use in children as young as 2 years. This is considered off-label use in an extremely vulnerable population. Even though several atypical antipsychotics are approved for pediatric use by the FDA, most are only approved for children as young as 10 years of age, and risperidone is indicated for children with autism as young as 5 years old. 16 There is a need for increased awareness and education to discourage the use of these medications in young children who could benefit from nonpharmacological approaches.
Even though many studies have reported the metabolic effects of atypical antipsychotics, we did not find any study that quantified both antidiabetic and antilipidemic medication use among children exposed to atypical antipsychotics. The results of this study add to the existing body of literature by not only estimating the prevalence of antidiabetic and antilipidemic medication use among children and adolescent atypical users but also by comparing the results with a nonexposed comparator group identified from the same database. This study had several limitations. First, because of the cross-sectional nature of the study, no causal relationship can be inferred between exposure to atypical antipsychotics and receipt of antidiabetic or antilipidemic medications. Second, we were unable to control for several confounders (eg, physical activity, obesity, diet, socioeconomic status, family history) that could affect metabolism. Confounding by indication may also be a potential limitation because some medications could have been prescribed to treat other conditions (eg, metformin is commonly used to treat polycystic ovarian syndrome in females). Third, the study has limited generalizability because it is representative of the Medicaid population of only 1 state at 1 point in time. Future research is needed to validate these results in a larger nationally representative population for a longer period of time. Fourth, we were not able to assess a temporal relationship between the prescription of antipsychotics and the prescription of antidiabetic or antilipidemic medications. As a result, we were only able to examine the pattern of concomitant use to generate hypotheses for future research. Fifth, the study groups were not randomized; therefore, inherent differences between the exposed and unexposed groups and between patients in the subgroups could bias results.
Conclusions
To our knowledge, this is the first study that has estimated the prevalence of both antidiabetic and antilipidemic medication use among children and adolescent atypical antipsychotic users. We estimated that use of these agents was about 2 times higher in atypical antipsychotic users as compared with nonusers. We found that Caucasian female and Caucasian male patients between the ages of 12 and 17 years of age exposed to atypical antipsychotics were more likely to receive concomitant antidiabetic and/or antilipidemic medication, respectively. Even though the prevalence estimates are small and these results cannot be generalized to a national population, they do provide some evidence of an association between atypical antipsychotic use and antidiabetic and antilipidemic medication use. The study adds to the existing body of evidence related to atypical antipsychotic-induced metabolic concerns. These results warrant the need for future studies in the area. Long-term prospective longitudinal studies controlling for prior antipsychotic exposure, multiple antipsychotic use, duration of treatment, and the temporal relationship between atypical antipsychotic use and antidiabetic and/or antilipidemic medication use are needed to establish a causal relationship between exposure to an atypical antipsychotic and antidiabetic and antilipidemic medication use. This study has highlighted important patterns of use that provide direction for future investigation.
